CAMBRIDGE, Mass. and TROY, N.Y.--(BUSINESS WIRE)--Alkermes, Inc. (Nasdaq: ALKS) and Rensselaer Polytechnic Institute today announced they have entered into a license agreement granting Alkermes exclusive rights to a family of novel opioid receptor compounds discovered at Rensselaer. These compounds represent an opportunity for Alkermes to develop important therapeutics for a broad range of diseases and medical conditions, including addiction, pain and other central nervous system (CNS) disorders. Alkermes will screen this library of compounds and plans to pursue preclinical work of an undisclosed, lead oral compound that has already been identified.
